What factors affect your first-line treatment choice for patients with metastatic colorectal cancer (mCRC)? What about initial treatment of a patient with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN)? Take a look at two very different patients and see if ERBITUX might be an option for their treatment plan.Meet Jay, a patient with mCRC Meet Neal, a patient with locoregionally advanced SCCHN
Find ERBITUX dosing information and dose modifications for infusion reactions and dermatologic toxicities.Go to dosing considerations
Making decisions and preparing for treatment may be a lot for patients and caregivers to handle. Learn about support resources that are available to help them understand what to expect with ERBITUX, including:
- Self-care Kit
- Financial Assistance
- Patient Brochures
- Patient Discussion Guide
- ERBITUX (cetuximab) [package insert]. Indianapolis, IN: Eli Lilly and Company, its subsidiaries or affiliates.